Abstract

Tissue calcification is an important physiological process required for the normal structure and function of bone. However, ectopic or excessive calcification contributes to diseases such as chondrocalcinosis, to calcium deposits in the skin or to vascular calcification. SMOC2 is a member of the BM-40/osteonectin family of calcium-binding secreted matricellular proteins. Using osteoprogenitor MC3T3-E1 cells stably overexpressing SMOC2, we show that SMOC2 inhibits osteogenic differentiation and extracellular matrix mineralization. Stable Smoc2 knockdown in these cells had no effect on mineralization suggesting that endogenous SMOC2 is not essential for the mineralization process. Mineralization in MC3T3-E1 cells overexpressing mutant SMOC2 lacking the extracellular calcium-binding domain was significantly increased compared to cells overexpressing full length SMOC2. When SMOC2 overexpressing cells were cultured in the presence of extracellular calcium supplementation, SMOC2’s inhibitory effect on calcification was rescued. Our observations were translationally validated in primary human periosteal-derived cells. Furthermore, SMOC2 was able to impair mineralization in transdifferentiated human umbilical vein endothelial cells. Taken together, our data indicate that SMOC2 can act as an inhibitor of mineralization. We propose a possible role for SMOC2 to prevent calcification disorders.

Highlights

  • Tissue calcification is an important and physiological process required for the normal structure and function of bone [1]

  • We assessed the secretion of SMOC2 protein in supernatants of differentiated Smoc2+ cells compared to 3.1+ cells by Western blot

  • We investigated the influence of SMOC2 on mineralization and calcification in different model systems

Read more

Summary

Introduction

Tissue calcification is an important and physiological process required for the normal structure and function of bone [1]. Calcification of the bone extracellular matrix gives the bone and body structure, helps to protect the inner organs and is a storage site from which calcium can be mobilized when required. SMOC2 inhibits calcification skeletal disorder in which calcium pyrophosphate crystals are deposited in the joints and tendons, triggering acute and painful inflammation [2]. Calcium crystal deposits occur in the skin in patients suffering from systemic sclerosis. Calcium crystal deposits can be found in arteries, a feature associated with increased cardiovascular risk. Vascular calcification most often occurs in patients suffering from diabetes, renal insufficiency or atherosclerosis [3,4,5]. There is need for effective strategies that prevent pathological calcification

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call